News

Tong, which is focused on the production, marketing and distribution of health sciences products, has a manufacturing facility located in Tongxiang, China. As part of the deal, Tong

The company is focused on developing and commercializing new medicines for the treatment of vitreo-retinal diseases. RVO is the third indication the company has underway for Jetrea. The

Avycaz is a combination of ceftazidime, a cephalosporin, and avibactam, a non-beta-lactam beta-lactamase inhibitor. The company said that currently only limited clinical safety and efficacy data for Avycaz

The trials will be carried out with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programed cell death ligand 1 (PD-L1)

The tablets are indicated to treat chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. The virus affects over 100 million

The open-label, multicenter, dose-escalation Phase I trial is designed to evaluate an intravenous (IV) formulation of marizomib in combination with bevacizumab (Avastin) in these patients. Patient enrollment is

GC Group is an Israeli pharmaceutical R&D firm engaged in development of several new generic drug products of different types. As part of the deal, GC Group will

The drug was granted orphan drug status under the US Orphan drug Act following a review by the FDA of a package of pre-clinical data submitted by the

MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARd) agonist currently being evaluated by the company in high unmet need and orphan diseases. Recently, MBX-8025 also